Incidence of Diabetes and Ischemic Heart Disease in COVID-19 Post Pandemic
Research Article Incidence of Diabetes and Ischemic Heart Disease in COVID-19 Post-Pandemic Raj Kamal Choudhry1* Submitted: October 20, 2024; Accepted: October 27, 2024; Published: October 28, 2024 Corresponding Author1*: Dr Raj Kamal Choudhry, Professor, MD Medicine, Department, Jawaharlal Medical College, Bhagalpur, Bihar, India; email: [email protected] Abstract Background: The long-term effects of the COVID-19 Pandemic are currently getting more attention. The majority of individuals with COVID-19 report having symptoms for a duration greater than four weeks following their initial appearance. After COVID-19 infection, there is worry that cardiovascular and metabolic conditions may be harmed. The severity of the sickness and COVID-19 vulnerability, meanwhile, are known to be linked to cardiometabolic risk. Aim: To study the incidence of ischemic heart disease and diabetes mellitus post-COVID-19 pandemic Methods and Materials: Information for all individuals diagnosed with COVID-19 was taken at the beginning of the investigation from the department’s release of electronic medical records in February 2021. The main outcomes analyzed were first-ever documented CVD as well as DM diagnoses. The data were then collected at different periods. They were as follows: Before the date of indexing. Acute: Follow up till four weeks from the index. Post-acute: Five to twelve weeks from the date of indexing. Long: Thirteen weeks to fifty-two weeks from the date of indexing. Poisson confidence intervals (CIs) were computed. Results: CVD events were 1362 in the COVID-19 study group, while 131 in the control study group at a phase corresponding to four weeks after the indexed date. CVD events were 781 in the COVID-19 study group, while 298 in the control study group were at a phase corresponding to five to twelve weeks since the indexing date. CVD events were 781 in the COVID-19 study group, while 298 in the control study group were at a phase corresponding to five to twelve weeks since the indexing date. CVD events were 2,134 in the COVID-19 study group, while 298 in the control study group were at a phase corresponding to 13 to 52 weeks since the indexing date. Conclusion: Early on, after COVID-19 infection, the risk of CVD is elevated, and this risk is elevated for up to three months. However, there is a long-term rise in the prevalence of CVD or DM in COVID-19 patients who do not already have these illnesses. Keywords: Prevalence, Cardiovascular disorders, diabetes mellitus, post COVID-19 Introduction The multiple organ systems illness known as Coronavirus Disease of 2019 (COVID-19) more universally acknowledged [1]. The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virus infects the respiratory system and causes host immune reactions that could have systemic implications by activating inflammatory mediators [2,3]. With the downregulated response of the immune system, irregular platelet aggregation, coagulopathy, endothelial cell malfunction, and thrombosis affecting different methods with a risk of end-organ harm, COVID-19 may cause an i”flammatory “cy”okine storm” [4]. While fresh cardiovascular disorders (CVD) and fresh cases of diabetes mellitus (DM) have been linked to initial COVID-19 contamination [5], longer-term consequences after the contamination have not been extensively described. Cardiac arrest, cardiac damage with raised troponin levels, and an increased morbidity and mortality probability among COVID-19-positive individuals who get hospitalized are some of the cardiac symptoms of COVID-19 [6,7]. In the first four weeks, COVID-19 can be additionally linked to sudden myocardial infarction and ischemic stroke [8-10]. Patients with COVID-19 have witnessed new-onset hyperglycemia, frequently referred to as “stress hy” euglycemia,” which has been linked with a poorer outcome [5,11]. Both existent and newly developed DM might have sequelae, such as hyperosmolarity condition and diabetic ketoacidosis condition [12–14]. Elevated concentrations of cytokine interleukin-6 (IL-6) and cytokine tumor necrosis factor-alpha (TNF) are indicative of direct pancreatic injury by SARS-CoV-2 and accompanying general inflammatory conditions seen in chronic post-COVID-19, which results in decreased pancreatic insulin production and insulin resistance [15,16]. The long-term effects of COVID-19 are currently getting more attention. The majority of individuals with COVID-19 report having symptoms for longer than 4 weeks following their initial appearance [17-19]. After COVID-19 infection, there is worry that cardiovascular conditions and metabolic conditions may be harmed. The severity of the sickness and COVID-19 vulnerability, meanwhile, are known to be linked to cardiometabolic risk. The recovery period following COVID-19 is still inadequately understood, though. With longitudinal data from digital medical records, it is possible to analyze COVID-19 results over a longer period. We conducted the study to compare a group of patients with COVID-19 exposure to a matched cohort of patients without a COVID-19 diagnosis. We sought to determine the overall impact of COVID-19 contamination on cardiovascular and metabolic consequences over four weeks, three months, and twelve months to identify areas for future research that may be most important and to guide clinical care and public health initiatives. Methods and Materials Data source and participant selection Information for all individuals diagnosed with COVID-19 was taken at the beginning of the investigation from the department’s release of electronic medical records in February 2021. The index deadline for COVID-19 contamination was the day of the first coding. We considered individuals with medical as”easement o” “co” firmed” or” “suspected” COVID-19 since conclusive testing was not generally accessible during the epidemic’s early stages. However, we performed a risk assessment using patients with a polymerase chain reaction (PCR) test validated COVID-19 medical coding documented. A subset of normal control patients without a history of COVID-19 contamination reported till the indexing date was contrasted to the COVID-19 group. Control participants were randomly selected from the March 2021 version registered populace, which offered the most recent data available in the database at the time of sampling. The records of controls were evaluated eighteen months before the beginning of the research, and they had to be compared for age, gender, and family practice. Patients who had widespread CVD or DM reported more than a year or within a year of the commencement of their record were not eligible to serve as controls. Outcome measures The main outcomes analyzed were the first-ever documented CVD and DM diagnoses. Stroke, venous thrombosis, pulmonary embolism, cardiomyopathy and myocarditis, heart failure, condition ischemic heart disease, condition of myocardial infarction, supraventricular tachycardia, atrial arrhythmias, atrial fibrillation
